New Data on PCSK9s for High Risk Groups

The results of the sub-group analyses of the FOURIER Trial showed patients who might benefit most from the combination of evolocumab and statin therapy, namely those with PAD and those who had a more recent MI, more than 1 MI, or residual multivessel disease. Those with the highest risk had the most benefit from the addition of evolocumab.

Read More

New: Behavior Change Mini-Certificate

Changing behaviors has never been easy, but PCNA now has a mini-certificate that can help. Our 8.25 CE contact hours program has two separate tracks – one for primary care and one for cardiac rehab.

Read More